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To test the hypothesis that plasminogen activator inhibitor-1 (PAI-1) may serve as a candidate marker for the malignancy of colorectal
cancer (CRC), we performed a quantitative RT–PCR for PAI-1 gene and evaluated the possible relationship between PAI-1 gene
expression levels and clinicopathological findings in CRC. A significant increase in PAI-1 expression scores was observed in lymph
node metastasis-positive CRCs (2.1970.43) compared to negative ones (0.3570.42) (P¼0.0037) as well as in distant metastasis-
positive CRCs (3.5071.18) compared to negative ones (0.9970.30). The PAI-1 expression score markedly increased with the
tumour stage (P¼0.0063; ANOVA test). Moreover, multivariate analysis revealed the PAI-1 expression score to be a strong and
independent prognostic factor for CRC (P¼0.0432). These results suggested that PAI-1 might serve as a new parameter for the
prediction of prognoses in CRC.
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There is now good evidence that a series of genetic alterations in
both dominant oncogenes and tumour suppressor genes are
involved in the pathogenesis of human colorectal cancer (CRC).
Activation of oncogenes such as the ras gene, and inactivation of
tumour suppressor genes such as the APC and p53 genes, have
been identified in CRC (Bos et al, 1987; Baker et al, 1990; Nishisho
et al, 1991). In addition, we found that several other genes are
related to the pathogenesis of this disease (Hibi et al, 1996, 1997,
2002, 2004; Yamazaki et al, 2002). An investigation of genetic
changes is important to clarify the tumorigenic pathway of CRC
(Vogelstein et al, 1988).
Plasminogen activator inhibitor-1 (PAI-1), a 45-kDa serine
proteinase inhibitor with a reactive peptide bond, Arg345–Met346,
is a multifaceted proteolytic inhibitor that not only functions as a
fibrinolytic inhibitor, but also plays an important role in signal
transduction, cell adherence, and cell migration. There is clinical
evidence implicating PAI-1 as a key factor in tumour invasion and
metastasis (Potempa et al, 1994; Lijnen, 2005). Moreover, PAI-1
has been linked to a poor prognosis in several cancers (Nekarda
et al, 1994; Cantero et al, 1997; Chambers et al, 1998; Foekens et al,
2000; Konecny et al, 2001). Previously, we also demonstrated that
PAI-1 expression was significantly correlated with a poor
prognosis in esophageal squamous carcinoma (Sakakibara et al,
2004). These results prompted us to examine the PAI-1 expression
level in other cancers, especially in CRC.
To test the hypothesis that PAI-1 may serve as a candidate
marker for the malignancy of CRC, we performed a quantitative
reverse transcription-PCR (RT–PCR) and evaluated the relation-
ship between the PAI-1 gene expression levels and clinicopatho-
logical findings in CRC.
MATERIALS AND METHODS
Patients and tissue specimens
The study group consisted of 55 CRC patients (mean age 64.5
years; range 41–85 years), who underwent surgical operations at
the Gastroenterological Surgery of the Nagoya University Graduate
School of Medicine from 1994 to 2002. Written informed consent,
as indicated by the institutional review board, was obtained from
all patients. All patients were followed at our hospital with
periodical examinations. The median follow-up was 33 months. In
total, 41, 4, and 10 patients received R0, R1, and R2 resection,
respectively. Although no patients received neoadjuvant therapy,
25 patients received adjuvant therapy. The distribution of these
patients was not related to PAI-1 expression scores. A total of 17
patients have been lost to follow-up until now. All tumours and
corresponding normal tissues were collected at the surgical
resection and stored at  801C. They were graded according to
their tumour-node-metastasis (TNM) stage as follows: 12 had stage
I disease; 12 had stage II; 23 had stage III; and eight had stage IV.
The patients were classified into two groups according to age, sex,
histology, tumour size, tumour site, depth of tumour invasion,
lymph node metastasis, perineal dissemination, carcinoembryonic
antigen (CEA), and TNM stage.
RNA preparation and reverse transcription
Total RNA was extracted from CRC and corresponding
normal tissues with guanidium thiocyanate as described pre-
viously (Hibi et al, 1996). The amount of RNA was measured
spectrophotometrically by absorbance at 260nm. First-strand
cDNA was generated from RNA as described previously (Hibi
et al, 1991).
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Quantitative RT–PCR was performed in an ABI sequence
detection system 7000 using SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA). Thermocycling was
carried out at a final volume of 50ml containing 2.0ml of the cDNA
sample, 1.0ml each of the PAI-1 primers (forward and reverse),
and 25ml of Mix SYBR Green I/Enzyme (including Taq DNA
polymerase, reaction buffer, and deoxynucleotide triphosphate
mixture). The PAI-1 primers for quantitative PCR were described
previously (Castello et al, 2002). PCR amplification consisted of 50
cycles (951C for 15s, 601C for 60s, and 721C for 18s) after an initial
denaturation step (951C for 10min). To correct for differences in
both quality and quantity among samples, GAPDH was used as an
internal control. GAPDH primers were purchased from Applied
Biosystems. Plasminogen activator inhibitor-1 and GAPDH mRNA
variability were determined from triplicate samples, the quantity of
which was in error by less than 10%. We applied an average
quantity of triplicated samples. The targets were obtained from the
same mRNA preparations.
PAI-1 expression score
We calculated the relative amounts of CRC (T) and corresponding
normal tissue (N) mRNA that we had normalised to an internal
control GAPDH mRNA. Next, we applied the logarithmic scale
as described previously (Pasco et al, 2001; Wang et al, 2003;
Sakakibara et al, 2004). We then defined the PAI-1 expression
score as follows:
log e ðthe relative amount of T=the relative amount of NÞ
Statistical and multivariate analyses
Data were expressed as means7s.e. Differences between the means
of analysed variables observed were calculated by the Student’s
t-test. The significance in correlations between tumour stages
and variables was determined by one-way ANOVA. Po0.05
(two-tailed) was considered significant. Survival rates were
calculated by the Kaplan–Meier method for analysis of censored
data. To compare the prognostic significance of the PAI-1
expression score with that of other parameters, multivariate
analysis was performed. Variables were eliminated from the model
one by one in a backward fashion and re-included only if the
P-value was less than 0.05.
RESULTS
We analysed PAI-1 expression levels in 55 CRC samples using a
quantitative RT–PCR. The mRNA concentrations were determined
after an extensive optimisation of PCR conditions, including
MgCl2 concentrations, reaction temperature, and cycling times.
This provided us with a highly sensitive, specific, and reproducible
real-time RT–PCR for specific detection of these mRNAs.
To determine the role of PAI-1 expression in CRC, we examined
the correlation of CRC expression scores with the clinico-
pathological features. Figure 1 shows the distribution of the
PAI-1 expression scores (the average was 1.3570.33). Figure 2
shows the differences in PAI-1 expression scores according to
lymph node metastasis. A significant increase in PAI-1 expression
scores was observed in lymph node metastasis-positive CRCs
(2.1970.43) compared to negative ones (0.3570.42) (P¼0.0037).
Figure 3 shows the differences in PAI-1 expression scores
according to distant metastasis. A significant increase in PAI-1
expression scores was observed in distant metastasis-positive
CRCs (3.5071.18) compared to negative ones (0.9970.30). These
results are summarised in Table 1. As shown in Figure 4, the PAI-1
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Figure 1 Distribution of PAI-1 expression scores in CRC (average was
1.3570.32).
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Figure 2 Difference in PAI-1 expression scores according to lymph node
metastasis. Upper and lower limits of boxes, and line across boxes, indicate
the 75th and 25th percentiles, and the median, respectively. Upper and
lower horizontal bars indicate maximal and minimal scores, respectively.
Outliers are illustrated as circles. Plasminogen activator inhibitor-1
expression scores were 2.1970.43 in metastasis-positive CRCs and
0.3570.42 in metastasis-negative ones (P¼0.0037; Student’s t-test).
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Figure 3 Difference in PAI-1 expression scores according to distant
metastasis: 3.5071.18 in metastasis-positive CRCs, and 0.9970.30 in
metastasis-negative ones (P¼0.0052; Student’s t-test).
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(stage I¼0.0170.63, stage II¼0.6670.61, stage III¼1.6770.36,
stage IV¼3.5071.18) (P¼0.0063; ANOVA test). We then
examined the cumulative survival of patient groups according to
their PAI-1 expression scores (more or less than 2). Interestingly,
the high PAI-1 expression-score group showed significantly poorer
survival rates than the low PAI-1 expression-score group (Figure 5,
Po0.0001).
To confirm the prognostic significance of the PAI-1 expression
score, other clinicopathological variables that might affect survival
were further analysed by Cox regression analysis. In univariate
analysis, the depth of tumour invasion (P¼0.0154), lymph node
involvement (Po0.0001), distant metastasis (Po0.0001), and
PAI-1 expression score (Po0.0001) were significantly correlated
with survival (Table 2). To determine the independent value and
the relative risk (RR) of these prognostic factors, multivariate
analysis was performed. Two prognostic factors were found to be
independent values: lymph node metastasis (P¼0.0267) and PAI-1
expression score (P¼0.0432). Taken together, these findings
showed that the PAI-1 expression score constituted a strong and
independent prognostic factor for CRC.
DISCUSSION
The plasminogen activation system plays a role in cancer
progression, presumably via extracellular matrix degradation and
tumour migration (Pedersen et al, 1994). It is generally believed
that serine protease, a urokinase-type plasminogen activator
(uPA), initiates a proteinase cascade at the cell surface and
Table 1 Clinicopathological features and PAI-1 expression scores in
colorectal cancer
Clinicopathological
feature Variable
No. of
cases
score
PAI-1
expression P value
a
Age o70 37 1.4870.42 0.59
X70 18 1.1070.51
Sex Male 37 1.6370.41 0.27
Female 18 0.8770.52
Histology tub
b 43 1.2570.40 0.54
por, muc, sig
c 12 1.7470.46
Tumour size (mm) o50 31 1.4970.71 0.45
X50 24 0.9270.35
Tumour site C, A, T
d 14 1.1770.47 0.75
D, S, R
e 41 1.4170.41
Depth of tumour invasion T1–T2 38 0.8470.30 0.016
T3–T4 17 2.5170.75
Lymph node metastasis N0 25 0.3570.42 0.0037
N1–N2 30 2.1970.43
Distant metastasis   47 0.9970.30 0.0052
+ 8 3.5071.18
Peritoneal dissemination   51 1.2370.34 0.17
+ 4 2.9770.96
aStudent’s t-test.
btub¼tubular adenocarcinoma.
cpor¼poorly differentiated
adenocarcinoma; muc¼mucinous adenocarcinoma; sig¼signet-cell adenocarcinoma.
dC¼cecum; A¼ascending colon; T¼transverse colon.
eD¼descending colon;
S¼sigmoid colon; R¼rectum.
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Figure 4 Differences in PAI-1 expression scores according to tumour
stages: 0.0170.63 in stage I, 0.6670.61 in stage II, 1.6770.0.36 in stage III,
and 3.5071.18 in stage IV (P¼0.0063; ANOVA).
Table 2 Risk factors for overall survival rate determined by univariate or multivariate analysis in colorectal cancer
Clinicopathological feature Variable Univariate Multivariate RR
a 95% CI
b
Lymph node N0/N1–N2 o0.0001 0.0267 11.0 1.3–92
Depth of tumour invasion T1–T2/T3–T4 0.0094 0.9850 1.0 0.23–4.3
Distant metastasis 7 o0.0001 0.2759 2.5 0.47–13
Peritoneal dissemination 7 0.0009 0.5978 1.5 0.32–7.0
PAI-1 p2.0/2.0oo 0.0001 0.0432 3.1 1.0–9.6
aRelative risk.
bConfidence interval.
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Figure 5 Cumulative survival of patient groups according to PAI-1
expression scores (more or less than 2). High PAI-1 expression-score
group showed significantly poorer survival rates than the low PAI-1
expression-score group (Po0.0001).
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spromotes tumour invasion and angiogenesis. Urokinase-type
plasminogen activator is frequently overexpressed in several
cancers and is a strong prognostic indicator for decreased patient
survival rates (Umeda et al, 1997; Duffy et al, 1999). Plasminogen
activator inhibitor-1, the protease inhibitor, is mainly synthesised
in vascular endothelial cells and regulates fibrinolytic activity in
the vasculature by controlling uPA activity. Recently, the involve-
ment of PAI-1 in tumour growth was suggested because of its high
expression levels in tumour extracts. At first, PAI-1 was expected
to inhibit tumour progression by inhibiting uPA activity on the
tumour cell surface. However, prognostic studies have indi-
cated that PAI-1 is also a clinical marker for a poor prognosis
in a variety of human cancers, suggesting that it plays an
important role in promoting tumour progression and invasion
(Grondahl-Hansen et al, 1993; Cho et al, 1997; Knoop et al,
1998). No clear explanation has yet been found for this
apparent paradox. Although the exact tumour biological functions
of PAI-1 remain uncertain, it is expressed in multiple cell
types and has multiple molecular interactions. This discrepancy
could be due to a difference in tumour histology, or it may
merely reflect the biological tumour features of different types of
cancer.
Tumour growth and metastasis are angiogenesis-dependent.
A tumour must continuously stimulate the growth of new
capillary blood vessels to promote its growth. Furthermore,
angiogenesis is required for tumour cells to enter the circulation
and metastasise to distant sites, such as liver, lung, or bone.
Tumour cells simultaneously secrete proteases (uPA) and their
inhibitors (PAI-1), and the balance between the two precisely
regulates the level of extracellular proteolysis, thus either
promoting or suppressing angiogenesis (Folkman et al, 2001). It
is likely that excess PAI-1 decreases cell adhesion to the
extracellular matrix by interfering with uPAR binding to
vitronectin, thus facilitating cell invasion and migration (Abe
et al, 1999). Other reports have also indicated that excess PAI-1
plays an important role in tumour growth and metastasis by
stimulating angiogenesis (McMahon et al, 2001; Bajou, 2002; Devy
et al, 2002). Recently, it has been reported that deficient PAI-1
expression in host mice prevented local invasion and tumour
vascularisation (Bajou et al, 1998). When this PAI-1 deficiency
was circumvented by an intravenous injection of a replication-
defective adenoviral vector expressing human PAI-1, the invasion
and its associated angiogenesis resumed. This experimental
evidence demonstrated that host-produced PAI-1 is essential
for cancer cell invasion and angiogenesis (Gutierrez et al, 2000;
Bajou et al, 2004).
In this study, we demonstrated for the first time that PAI-1
expression increased with the CRC stage and was associated with a
poor prognosis. In univariate analysis, the PAI-1 expression score
was significantly correlated with survival of CRC. Moreover, in
multivariate analysis, the PAI-1 expression score was a strong and
independent prognostic factor in CRC, second to the lymph node
involvement. These results suggested that PAI-1 might serve as a
new parameter for the prognostic prediction of CRC.
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